



SLOVENSKI STANDARD
oSIST prEN ISO 14155:2024
01-september-2024

**Klinične raziskave medicinskih pripomočkov za ljudi - Dobre klinične prakse
(ISO/DIS 14155:2024)**

Clinical investigation of medical devices for human subjects - Good clinical practice
(ISO/DIS 14155:2024)

Klinische Prüfung von Medizinprodukten an Menschen - Gute klinische Praxis (ISO/DIS
14155:2024)

Investigation clinique des dispositifs médicaux pour sujets humains - Bonne pratique
clinique (ISO/DIS 14155:2024)

Ta slovenski standard je istoveten z: prEN ISO 14155

oSIST prEN ISO 14155:2024

<https://standards.sist.si/catalog/standards/sist/030d2d7c-3a97-4563-ab77-c57626c3ccda/ost-norm-pron-iso-14155-2024>

ICS:

11.040.01	Medicinska oprema na splošno	Medical equipment in general
-----------	------------------------------	------------------------------

oSIST prEN ISO 14155:2024

en,fr,de



DRAFT International Standard

ISO/DIS 14155

Clinical investigation of medical devices for human subjects — Good clinical practice

*Investigation clinique des dispositifs médicaux pour sujets
humains — Bonne pratique clinique*

ICS: 11.100.20

ISO/TC 194

Secretariat: DIN

Voting begins on:
2024-06-20

Voting terminates on:
2024-09-12

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[oSIST prEN ISO 14155:2024](https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024)

<https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024>

This document is circulated as received from the committee secretariat.

ISO/CEN PARALLEL PROCESSING

Reference number
ISO/DIS 14155:2024(en)

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENTS AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

© ISO 2024

ISO/DIS 14155:2024(en)

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[oSIST prEN ISO 14155:2024](https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024)

<https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2024

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

ISO/DIS 14155:2024(en)

Contents

	Page
Foreword	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Summary of good clinical practice (GCP) principles	9
5 Ethical considerations	10
5.1 General.....	10
5.2 Improper influence or inducement.....	10
5.3 Compensation and additional health care.....	10
5.4 Registration in publicly accessible database.....	10
5.5 Responsibilities.....	10
5.6 Communication with the ethics committee (EC).....	11
5.6.1 General.....	11
5.6.2 Initial EC submission.....	11
5.6.3 Information to be obtained from the EC.....	11
5.6.4 Continuing communication with the EC.....	11
5.6.5 Continuing information to be obtained from the EC.....	12
5.7 Vulnerable populations.....	12
5.8 Informed consent.....	12
5.8.1 General.....	12
5.8.2 Process of obtaining informed consent.....	13
5.8.3 Special circumstances for informed consent.....	13
5.8.4 Information to be provided to the subject.....	14
5.8.5 Informed consent signature.....	16
5.8.6 New information.....	17
6 Clinical investigation planning	17
6.1 General.....	17
6.2 Risk management.....	17
6.2.1 General.....	17
6.2.2 Risks related to the use of the investigational device and their disclosure.....	17
6.2.3 Clinical investigation process.....	18
6.3 Justification for the design of the clinical investigation.....	18
6.4 Clinical investigation plan (CIP).....	19
6.5 Investigator's brochure (IB).....	19
6.6 Case report forms (CRFs).....	19
6.7 Monitoring plan.....	20
6.8 Investigation site selection.....	21
6.9 Agreement(s).....	21
6.10 Labelling.....	21
6.11 Data monitoring committee (DMC).....	21
6.12 Clinical events committee (CEC).....	21
7 Clinical investigation conduct	22
7.1 General.....	22
7.2 Investigation site initiation.....	22
7.3 Investigation site monitoring.....	22
7.4 Adverse events and device deficiencies.....	22
7.4.1 Signals requiring immediate action.....	22
7.4.2 Adverse events.....	23
7.4.3 Device deficiencies.....	23
7.4.4 Risk assessment process for potentially unacceptable risks related to the use of the investigational device.....	23
7.4.5 Management of risks related to clinical procedures required by the CIP.....	24
7.5 Clinical investigation documents and documentation.....	24

ISO/DIS 14155:2024(en)

7.5.1	Amendments.....	24
7.5.2	Subject identification log.....	25
7.5.3	Source documents.....	25
7.6	Additional members of the investigation site team.....	25
7.7	Subject privacy and confidentiality of data.....	25
7.8	Document and data control.....	25
7.8.1	Traceability of documents and data.....	25
7.8.2	Recording of data.....	26
7.8.3	Electronic clinical data systems.....	26
7.9	Investigational device accountability.....	27
7.10	Accounting for subjects.....	27
7.11	Auditing.....	27
8	Suspension, termination, and close-out of the clinical investigation.....	28
8.1	Completion of the clinical investigation.....	28
8.2	Suspension or premature termination of the clinical investigation.....	28
8.2.1	General.....	28
8.2.2	Suspension.....	29
8.2.3	Procedure for premature termination.....	29
8.2.4	Procedure for resuming the clinical investigation after suspension.....	29
8.3	Routine close-out.....	30
8.4	Clinical investigation report.....	30
8.5	Risk assessment and conclusions.....	31
8.6	Document retention.....	31
9	Responsibilities of the sponsor.....	31
9.1	Clinical quality management.....	31
9.2	Clinical investigation planning and conduct.....	32
9.2.1	Selection and training of clinical personnel.....	32
9.2.2	Preparation of documents and materials.....	33
9.2.3	Conduct of clinical investigation.....	33
9.2.4	Monitoring.....	34
9.2.5	Safety evaluation and reporting.....	36
9.2.6	Clinical investigation close-out.....	37
9.3	Outsourcing of duties and functions.....	37
9.4	Communication with regulatory authorities.....	38
10	Responsibilities of the principal investigator.....	38
10.1	General.....	38
10.2	Qualification of the principal investigator.....	38
10.3	Qualification of investigation site.....	39
10.4	Communication with the EC.....	39
10.5	Informed consent process.....	39
10.6	Compliance with the CIP.....	39
10.7	Medical care of subjects.....	40
10.8	Safety reporting.....	41
	Annex A (normative) Clinical investigation plan (CIP).....	42
	Annex B (normative) Investigator's brochure (IB).....	50
	Annex C (informative) Case report forms (CRFs).....	53
	Annex D (normative) Clinical investigation report.....	55
	Annex E (informative) Essential clinical investigation documents.....	60
	Annex F (informative) Adverse event categorization.....	67
	Annex G (informative) EC responsibilities.....	69
	Annex H (informative) Application of ISO 14971 during clinical investigations.....	73
	Annex I (informative) Clinical development stages.....	74
	Annex J (informative) Clinical investigation audits.....	79

ISO/DIS 14155:2024(en)

Annex K (informative) Clinical investigation design considerations	82
Annex ZA (informative) Relationship between this European standard and the requirements of Regulation (EU) 2017/745 aimed to be covered	84
Bibliography	91

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[oSIST prEN ISO 14155:2024](https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024)

<https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024>

ISO/DIS 14155:2024(en)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO *had not* received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This fourth edition cancels and replaces the third edition (ISO 14155:2020), which has been technically revised. The main changes to the previous edition are as follows:

- Change in definition of clinical performance ([3.12](#));
- Clarification about deviations from eligibility criteria not being permitted but subject to CIP amendment (see [5.6.4](#));
- Clarified informed consent to be obtained where applicable from subject's legally designated representative (see [5.8.1](#));
- Clarified subject must be given opportunity to discuss participation with others e.g. family members (see [5.8.2](#));
- Clarification on risk management clear distinction between risks related to the use of the device and risks related to the procedures required by the CIP which are not part of normal clinical practice (see [6.2.1](#));
- Inclusion of required assessment of residual risks including quantified estimation (see [6.2.2](#));
- Correction of reference to risks related to the use of the investigational device (see [6.2.1](#), [7.4.4](#), [8.2 Annex F](#), [Annex H](#) and [3.2](#));
- Added normative requirements (previously in [Annex A](#)) to [6.4](#);
- Added requirement for data monitoring committee to confirm conditions for suspending or stopping the clinical investigation (see [6.11](#));
- Inclusion of new section on clinical events committee (see [3.7](#), [6.12](#) and [A.14](#));

ISO/DIS 14155:2024(en)

- Clarify situations of reduced adverse events reporting requirements (see [7.4.2](#));
- Inclusion of management of risks related to clinical procedures required by the CIP (see [7.4.5](#));
- Clarified process of suspension or premature termination of the clinical investigation also in line with updated [sections 7.4.4](#) and [Figure H.1](#) (see [8.2](#));
- Update of procedure section in CIP with methods and timing for assessing, recording and analysing variables and added requirement for calibration of equipment (see [A.6.4](#));
- Clarified requirements for non-inferiority margins and missing data (see [A.7](#));
- Added requirement to justify absence of DMC involvement (see [A.14](#));
- Added requirement for subject follow up and continued care to include those different from normal practice (see [A.16](#));
- Clarification on local representative for better harmonisation with national regulatory requirements (see [9.2.1](#));
- Include requirement for implant card (see [9.2.2](#));
- Moved general requirements to [clause 6.4](#) on objective and study design (see [A.5](#));
- Updated adverse events categorization clarifying terminology in updated flowchart F1 (see [Annex F](#));
- Clarification in [Annex H](#) in line with [6.2.1](#) and updated flowchart (see [Annex H](#));
- Inclusion of estimands and their attributes (see, [6.4](#), [A.5](#), [A.6](#), [A.7](#), new [Annex K](#));
- Inclusion of precautions (see [Clause B.5](#)), information on training on the use of investigational device (see [B.2](#)), and in-silico tests (see [B.3](#)).

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Document Preview

[oSIST prEN ISO 14155:2024](#)

<https://standards.iteh.ai/catalog/standards/sist/85bd2d7e-5a91-4365-abf4-c37026c5ceda/osist-pren-iso-14155-2024>

Clinical investigation of medical devices for human subjects — Good clinical practice

1 Scope

This document addresses good clinical practice for the design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the clinical performance or effectiveness and safety of medical devices.

For post-market clinical investigations, the principles set forth in this document are intended to be followed as far as relevant, considering the nature of the clinical investigation (see [Annex I](#)).

This document specifies general requirements intended to:

- protect the rights, safety and well-being of human subjects,
- ensure the scientific conduct of the clinical investigation and the credibility of the clinical investigation results,
- define the responsibilities of the sponsor and principal investigator, and
- assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

NOTE 1 Users of this document need to consider whether other standards and/or national requirements also apply to the investigational device(s) under consideration or the clinical investigation. If differences in requirements exist, the most stringent apply.

NOTE 2 For Software as a Medical Device (SaMD) demonstration of the analytical validity (the SaMD's output is accurate for a given input), and where appropriate, the scientific validity (the SaMD's output is associated to the intended clinical condition/physiological state), and clinical performance (the SaMD's output yields a clinically meaningful association to the target use) of the SaMD, the requirements of this document apply as far as relevant (see Reference [5]). Justifications for exemptions from this document can consider the uniqueness of indirect contact between subjects and the SaMD. This document does not apply to *in vitro* diagnostic medical devices. However, there can be situations, dependent on the device and national or regional requirements, where users of this document might consider whether specific sections and/or requirements of this document could be applicable.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14971, *Medical devices — Application of risk management to medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

ISO/DIS 14155:2024(en)

3.1 adverse device effect

ADE

adverse event (3.2) related to the use of an *investigational medical device* (3.30)

Note 1 to entry: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any *malfunction* (3.34) of the investigational medical device.

Note 2 to entry: This definition includes any event resulting from *use error* (3.53) or from intentional misuse of the investigational medical device.

Note 3 to entry: This includes ‘*comparator*’ (3.13) if the comparator is a medical device.

3.2 adverse event

AE

untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including abnormal laboratory findings) in *subjects* (3.51), users or other persons, whether or not related to the *investigational medical device* (3.30) and whether anticipated or unanticipated

Note 1 to entry: This definition includes events related to the investigational medical device or the *comparator* (3.13).

Note 2 to entry: This definition includes events related to the use of the investigational medical device and the clinical procedure(s) required by the CIP that are additional to normal clinical practice.

Note 3 to entry: For users or other persons, this definition is restricted to events related to the use of investigational medical devices or comparators.

3.3 audit

systematic examination of activities and documents related to a *clinical investigation* (3.9) performed by (an) *independent* (3.27) person(s), to determine whether these activities were conducted, and the data recorded, analysed and accurately reported, according to the CIP, standard operating procedures, this document and applicable regulatory requirements

3.4 audit trail

documentation that allows reconstruction of the course of events

3.5 blinding masking

procedure in which one or more parties to the *clinical investigation* (3.9) are kept unaware of the treatment assignment(s)

Note 1 to entry: Single blinding usually refers to the *subject(s)* (3.51) being unaware of the treatment assignment(s). Double blinding usually refers to the *subject(s)*, *investigator(s)* (3.31), monitor and, in some cases, centralized assessors being unaware of the treatment assignment(s).

Note 2 to entry: A clinical investigation is termed ‘observer blind’, if at least the *primary endpoint(s)* (3.23) is/are assessed without knowledge of whether an *investigational medical device* (3.30) or *comparator* (3.13) has been used to treat a subject.

3.6 case report form

CRF

set of printed, optical or electronic documents for each *subject* (3.51) on which information to be reported to the *sponsor* (3.50) is recorded, as required by the CIP

ISO/DIS 14155:2024(en)

3.7

Clinical events committee

CEC

independent committee of clinical experts that can be established by the sponsor to ensure consistent event assessment across participating centres and mitigate inadequate reporting risks

Note 1 to entry: For the purpose of this document, “central events committee”, “clinical adjudication committee (CAC)”, “endpoint adjudication committee (EAC)” are synonymous with CEC.

3.8

certified copy

copy (irrespective of the type of media used) of the original record that has been verified (i.e. by a dated signature or by generation through a validated process) to have the same information including data that describe the context, content, and structure, as the original

3.9

clinical investigation

systematic investigation in one or more human *subjects* (3.51), undertaken to assess the *clinical performance* (3.12), *effectiveness* (3.21) or safety of a *medical device* (3.35)

Note 1 to entry: For the purpose of this document, “clinical trial” or “clinical study” are synonymous with “clinical investigation”.

3.10

clinical investigation plan

CIP

document that states the rationale, *objectives* (3.38), design and pre-specified analysis, methodology, organization, *monitoring* (3.36), conduct and record-keeping of the *clinical investigation* (3.9)

Note 1 to entry: For the purpose of this document “protocol” is synonymous with “CIP”. However, protocol has many different meanings, some not related to clinical investigation, and these can differ from country to country. Therefore, the term CIP is used in this document.

3.11

clinical investigation report

document describing the design, conduct, statistical analysis and results of a *clinical investigation* (3.9)

3.12

clinical performance

ability of a *medical device* (3.35), resulting from any direct or indirect medical effects which stem from its technical or functional characteristics, including diagnostic characteristics, to achieve its intended purpose as claimed by the manufacturer, thereby leading to a clinical benefit for *subject(s)* (3.51), when used as intended by the manufacturer

Note 1 to entry: Clinical performance can be defined under national regulations.

3.13

comparator

medical device (3.35), therapy (e.g. active treatment, normal clinical practice), placebo or no treatment, used in the *control group* (3.16) in a *clinical investigation* (3.9)

3.14

computer system

hardware and software (including associated documents, e.g. user manual) that creates, modifies, maintains, archives, retrieves, or transmits in digital form information related to the conduct of a *clinical investigation* (3.9)

3.15

contract research organization

CRO

person or organization contracted by the *sponsor* (3.50) to perform one or more of the sponsor's clinical investigation-related duties and functions

ISO/DIS 14155:2024(en)

3.16

control group

group of *subjects* (3.51) that receives the *comparator* (3.13)

Note 1 to entry: A control group may be concurrent or historical, or subjects may serve as their own control.

3.17

coordinating investigator

investigator (3.31) who is appointed by the *sponsor* (3.50) to assist in coordinating the work in a multicentre *clinical investigation* (3.9)

Note 1 to entry: For the purpose of this document, “national investigator” or “global investigator” are synonymous with “coordinating investigator”.

3.18

data monitoring committee

DMC

independent (3.27) committee that can be established by the *sponsor* (3.50) to assess, at intervals, the progress of the *clinical investigation* (3.9), the safety data or the critical *clinical performance* (3.12) or *effectiveness* (3.21) *endpoints* (3.23, 3.24) and to recommend to the sponsor whether to continue, suspend, modify, or stop the clinical investigation

Note 1 to entry: For the purpose of this document, “data and safety monitoring board (DSMB)”, “data and safety monitoring committee (DSMC)” or “independent data monitoring committee (IDMC)” are synonymous with DMC.

3.19

deviation

instance of failure to follow, intentionally or unintentionally, the requirements of the *CIP* (3.10)

3.20

device deficiency

inadequacy in the identity, quality, durability, reliability, usability, safety or performance of a *medical device* (3.35), including *malfunctions* (3.34), *use errors* (3.53), or inadequacy in the information supplied by the manufacturer including labelling

Note 1 to entry: This definition includes device deficiencies related to the *investigational medical device* (3.30) or the *comparator* (3.13).

3.21

effectiveness

achievement of a clinically meaningful intended result in a defined portion of the target population when the *investigational medical device* (3.30) is used within its intended uses and according to its instructions for use, the *investigator’s brochure* (3.32) and the *CIP* (3.10), as determined by documented scientific evidence

3.22

electronic record

combination of text, graphics, data, audio, imaging, or other information in digital form that is created, modified, maintained, archived, retrieved, or distributed by a *computer system* (3.14)

EXAMPLE An electronic CRF.

3.23

endpoint

<primary> principal indicator(s) used for providing the evidence for *clinical performance* (3.12), *effectiveness* (3.21) or safety in a *clinical investigation* (3.9)

3.24

endpoint

<secondary> indicator(s) used for assessing the secondary *objectives* (3.38) of a *clinical investigation* (3.9)